| Old Articles: <Older 20961-20970 Newer> |
|---|
 |
The Motley Fool
February 22, 2007
Rich Duprey |
Aaron Rents Sprouting Growth Amid an aggressive new store opening plan, sales and profits continue to rise. Investors, take note.   |
The Motley Fool
February 22, 2007
Jeremy MacNealy |
Fool on Call: Guess? Is a Diaper Dandy In the spirit of March Madness, will Guess? maintain its hot touch from beyond the arc in fiscal 2008? Or will this diaper dandy lose its hunger for victory, get out of shape, and become a has-been? |
The Motley Fool
February 22, 2007
Ryan Fuhrmann |
Fashionable Results From J.C. Penney: Fool by Numbers The department store retailer released fourth-quarter and year-end 2006 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 22, 2007
Brian Lawler |
Too Much Aplomb From Elan Elan releases its 2006 financial results, and its future is not as rosy as seems. Investors, take note. |
The Motley Fool
February 22, 2007
Nathan Parmelee |
Quick Take: U-Store-It, Someplace Else The founding family has been evicted at U-Store-It Trust. Investors, this is bound to prove interesting as more facts come out. |
The Motley Fool
February 22, 2007
Ryan Fuhrmann |
Skechers' Shoe Fits: Fool by Numbers The footwear designer and retailer released fourth-quarter and year-end 2006 results. Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 22, 2007 |
Putting on the Ritz at Abercrombie & Fitch: Fool by Numbers The retailer released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 22, 2007
Brian Lawler |
Dueling Fools: Pfizer Bear Rebuttal Generic competition for Lipitor is just the beginning. Faith is nice in terms of religion, but when it comes to investments, investors need to be able to make some reasonable assumptions about future growth plans. |
The Motley Fool
February 22, 2007
Ryan Fuhrmann |
Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note. |
The Motley Fool
February 22, 2007
Brian Lawler |
Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today. |
| <Older 20961-20970 Newer> Return to current articles. |
